Internal Medicine, Hematology & Oncology · Ponce, PR
NPI
1992981690
Since 2008
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
609 Ave Tito Castro Ste 102, Pmb 359
Ponce, PR, 00716
Phone (787) 548-8412
Groups this clinician bills Medicare through
Medicare paid, 2024
$390K
14,497 services
Medicare patients, 2024
35
Average age 78
Drug cost, 2024
$7.8M
3,127 prescriptions
Company payments, 2025
$3,199
From 24 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Anna M Di Marco was code J7040 (infusion, normal saline solution, sterile (500 ml = 1 unit)), 74 times for 15 patients. In total Anna M Di Marco billed 14,497 services in 31 codes, and Medicare paid $390K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-10-23.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit) | Office | 74 | 15 | $0.84 | $61.92 |
| 96366 Intravenous Infusion, Hydration | Office | 71 | 13 | $15.06 | $1,070 |
| 99214 Office E&M - Established | Office | 56 | 31 | $74.59 | $4,177 |
| 96365 Intravenous Infusion, Hydration | Office | 38 | 14 | $44.71 | $1,699 |
By year: 2022 $183K for 12,622 services; 2023 $184K for 9,623 services; 2024 $390K for 14,497 services.
Medicare prescription drug claims, 2024
In 2024, the drug Anna M Di Marco prescribed most often to Medicare patients was Anastrozole, with 1,365 prescriptions and refills. In total Anna M Di Marco wrote 3,127 Medicare prescriptions that cost $7.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 1,365 | 1,709 | 227 | $23K |
| Ibrance Palbociclib | 156 | 156 | 19 | $2.5M |
| Exemestane Generic | 98 | 112 | 15 | $6,120 |
| Ondansetron Hcl Ondansetron Hcl/Pf | 72 | 75 | 14 | $357 |
| Dexamethasone Sodium Phosphate Generic | 70 | 72 | 19 | $510 |
| Diphenhydramine Hcl Generic | 70 | 72 | 17 | $344 |
| Ondansetron Hcl Generic | 67 | 67 | 28 | $441 |
| Famotidine Famotidine/Pf | 64 | 65 | 13 | $290 |
| Sodium Chloride 0.9 % Sodium Chloride | 52 | 64 | 51 | $285 |
| Hydroxyurea Generic | 49 | 51 | Under 11 | $922 |
| Retacrit Epoetin Alfa-Epbx | 37 | 37 | 29 | $65K |
| Revlimid Lenalidomide | 36 | 36 | Under 11 | $784K |
| Tamoxifen Citrate Generic | 36 | 38 | Under 11 | $861 |
| Lenvima Lenvatinib Mesylate | 33 | 33 | Under 11 | $1.0M |
| Kadcyla Ado-Trastuzumab Emtansine | 32 | 32 | Under 11 | $281K |
Brand drugs: 677 claims; generic drugs: 2,450 claims; opioid claims: 19.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Anna M Di Marco $3,199 ($3,199 in general payments such as food, travel and fees) from 24 companies. The largest payer was E.R. Squibb & Sons, L.L.C. with $471.
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. BMY | 20 | $471 |
| AstraZeneca Pharmaceuticals LP AZN | 16 | $357 |
| Abbvie Inc. ABBV | 12 | $278 |
| Janssen Pharmaceuticals, Inc JNJ | 12 | $269 |
| Merck Sharp & Dohme LLC MRK | 13 | $259 |
| Pbg Puerto Rico LLC | 9 | $208 |
| Gilead Sciences, Inc. GILD | 11 | $160 |
| Genentech USA, Inc. ROG.SW | 6 | $126 |
| GlaxoSmithKline, LLC. GSK | 5 | $121 |
| Genzyme Corporation SNY | 5 | $112 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.